Pfizer announces outcome of FDA advisory committee meeting for SUTENT®
Pfizer announced the FDA Oncologic Drug Advisory Committee voted 6 in favor and 6 against the benefit-risk profile for SUTENT® (sunitinib) as adjuvant treatment of adult patients at high risk of RCC after nephrectomy (surgical removal of the cancer-containing kidney). September 19, 2017